CO2023014888A2 - Anticuerpos - Google Patents
AnticuerposInfo
- Publication number
- CO2023014888A2 CO2023014888A2 CONC2023/0014888A CO2023014888A CO2023014888A2 CO 2023014888 A2 CO2023014888 A2 CO 2023014888A2 CO 2023014888 A CO2023014888 A CO 2023014888A CO 2023014888 A2 CO2023014888 A2 CO 2023014888A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- trem1
- bind
- inhibit
- interaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183280P | 2021-05-03 | 2021-05-03 | |
| PCT/EP2022/061661 WO2022233764A1 (en) | 2021-05-03 | 2022-05-02 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014888A2 true CO2023014888A2 (es) | 2024-04-29 |
Family
ID=81878071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014888A CO2023014888A2 (es) | 2021-05-03 | 2023-10-31 | Anticuerpos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240254224A1 (https=) |
| EP (1) | EP4334355A1 (https=) |
| JP (1) | JP2024516305A (https=) |
| KR (1) | KR20240004694A (https=) |
| CN (1) | CN117642428A (https=) |
| AR (1) | AR125732A1 (https=) |
| AU (1) | AU2022268545A1 (https=) |
| BR (1) | BR112023022844A2 (https=) |
| CA (1) | CA3218933A1 (https=) |
| CL (1) | CL2023003241A1 (https=) |
| CO (1) | CO2023014888A2 (https=) |
| IL (1) | IL308100A (https=) |
| MX (1) | MX2023012984A (https=) |
| TW (1) | TW202309089A (https=) |
| WO (1) | WO2022233764A1 (https=) |
| ZA (1) | ZA202309815B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260017009A (ko) | 2023-04-21 | 2026-02-04 | 셀시우스 테라퓨틱스, 인코포레이티드 | 항-trem1 항체 제제, 조성물 및 이의 용도 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| PT1049787E (pt) | 1998-01-23 | 2005-04-29 | Vlaams Interuniv Inst Biotech | Derivados de anticorpos multipropositos |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| WO2013068571A1 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
| JP6411218B2 (ja) * | 2012-02-15 | 2018-10-24 | ノヴォ ノルディスク アー／エス | 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| WO2019195126A1 (en) * | 2018-04-02 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| GB201809341D0 (en) | 2018-06-07 | 2018-07-25 | Ucb Biopharma Sprl | Multi-domain proteins with increased native state colloidal stability |
| US10836828B2 (en) * | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
-
2022
- 2022-05-02 IL IL308100A patent/IL308100A/en unknown
- 2022-05-02 CN CN202280046100.0A patent/CN117642428A/zh active Pending
- 2022-05-02 WO PCT/EP2022/061661 patent/WO2022233764A1/en not_active Ceased
- 2022-05-02 US US18/558,686 patent/US20240254224A1/en active Pending
- 2022-05-02 BR BR112023022844A patent/BR112023022844A2/pt unknown
- 2022-05-02 KR KR1020237040994A patent/KR20240004694A/ko active Pending
- 2022-05-02 AU AU2022268545A patent/AU2022268545A1/en active Pending
- 2022-05-02 EP EP22727056.8A patent/EP4334355A1/en active Pending
- 2022-05-02 JP JP2023568038A patent/JP2024516305A/ja active Pending
- 2022-05-02 CA CA3218933A patent/CA3218933A1/en active Pending
- 2022-05-02 AR ARP220101137A patent/AR125732A1/es unknown
- 2022-05-02 MX MX2023012984A patent/MX2023012984A/es unknown
- 2022-05-03 TW TW111116603A patent/TW202309089A/zh unknown
-
2023
- 2023-10-20 ZA ZA2023/09815A patent/ZA202309815B/en unknown
- 2023-10-31 CL CL2023003241A patent/CL2023003241A1/es unknown
- 2023-10-31 CO CONC2023/0014888A patent/CO2023014888A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003241A1 (es) | 2024-06-21 |
| AU2022268545A1 (en) | 2023-11-02 |
| IL308100A (en) | 2023-12-01 |
| AU2022268545A9 (en) | 2023-11-16 |
| BR112023022844A2 (pt) | 2024-01-23 |
| MX2023012984A (es) | 2023-11-15 |
| WO2022233764A1 (en) | 2022-11-10 |
| KR20240004694A (ko) | 2024-01-11 |
| CA3218933A1 (en) | 2022-11-10 |
| AR125732A1 (es) | 2023-08-09 |
| TW202309089A (zh) | 2023-03-01 |
| CN117642428A (zh) | 2024-03-01 |
| JP2024516305A (ja) | 2024-04-12 |
| EP4334355A1 (en) | 2024-03-13 |
| US20240254224A1 (en) | 2024-08-01 |
| ZA202309815B (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000701A1 (es) | Anticuerpos que se unen a il1rap y usos de los mismos | |
| CO2020001983A2 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39 | |
| UY37258A (es) | AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS | |
| CL2023002048A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos | |
| CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| BR112017011166A2 (pt) | anticorpos heterodiméricos que se ligam a cd3 e cd38 | |
| ECSP20029142A (es) | Ligandos de psma para la formación de imágenes y endorradioterapia | |
| MX2022008781A (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos. | |
| MX2018003196A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| CL2017002752A1 (es) | Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales | |
| MX385936B (es) | Anticuerpos biespecíficos que se unen a cd38 y cd3. | |
| BR112021020999A2 (pt) | Polipeptídeos de ligação à clec12a e usos dos mesmos | |
| ECSP13012724A (es) | Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| BR112016000903A2 (pt) | anticorpos | |
| EA201890093A1 (ru) | Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина | |
| MX2017012352A (es) | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. | |
| MX2024003463A (es) | Anticuerpos anti-edb y conjugados anticuerpo-farmaco. | |
| CL2021000347A1 (es) | Polipéptidos de unión a ox40 y sus usos | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| MX2018000839A (es) | Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos. | |
| CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
| MX394735B (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| CL2023003241A1 (es) | Anticuerpos |